Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02121301 · ClinicalTrials.gov registry record · Phase 2
A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)
A Phase 2 study, sponsored by Mitotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT02121301: Completed Phase 2 study, sponsored by Mitotech.
NCT02121301 is a Phase 2 study that has completed, run by Mitotech. The registered enrollment target is 91 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02121301, a Phase 2 study, has completed, sponsored by Mitotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
Primary Outcome
The dry eye sign primary efficacy variable of corneal fluorescein staining of the inferior region of the eye measured on a 0-4 point scale where 0 = no staining and 4 = most staining between treatment arms at day 29
Interventions
- DRUG Low Dose 0.155µg/mL SkQ1 ophthalmic solution
- DRUG High Dose 1.55µg/mL SkQ1 ophthalmic solution
- DRUG Placebo (Vehicle) opthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
What the finished NCT02121301 record still lists
NCT02121301 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 3 interventions - of which Low Dose 0.155µg/mL SkQ1 ophthalmic solution is the first listed.
NCT02121301 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02121301 about?
NCT02121301 is a clinical study titled "A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)". The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
What is the current status of trial NCT02121301?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2014-04. Estimated completion is 2014-06.
What interventions are being tested in trial NCT02121301?
The interventions under investigation include: Low Dose 0.155µg/mL SkQ1 ophthalmic solution (DRUG), High Dose 1.55µg/mL SkQ1 ophthalmic solution (DRUG), Placebo (Vehicle) opthalmic solution (DRUG).
Who is sponsoring clinical trial NCT02121301?
This trial is sponsored by Mitotech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02121301's enrollment target sits among peer trials
91 771st of 2000 higher than 1,229 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia